IP Library › Granted Patent US 12,738,382
Granted Patent B2
US 12,738,382 · App. 18/342,852 · Granted Sep 15, 2026

ECG-based cardiovascular disease detection systems and related methods

Inventors: Alvaro E. Ulloa-Cerna (Danville, PA); Noah Zimmerman (Chicago, IL); Greg Lee (Chicago, IL); Christopher M. Haggerty (Danville, PA); Brandon K. Fornwalt (Danville, PA); Ruijun Chen (Danville, PA); John Pfeifer (Danville, PA); Christopher Good (Danville, PA)
Assignees: Tempus AI, Inc.; Geisinger Clinic
G16H50/30A61B5/0006A61B5/28A61B5/318A61B5/7275G16H50/20G06F18/2155
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,738,382
App. No.
18/342,852
Granted
Sep 15, 2026
Kind
B2
Abstract

A method for determining cardiology disease risk from electrocardiogram trace data and clinical data includes receiving electrocardiogram trace data associated with a patient, receiving the patient's clinical data, providing both sets of data to a trained machine learning composite model that is trained to evaluate the data with respect to each disease of a set of cardiology diseases including three or more of cardiac amyloidosis, aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation, tricuspid regurgitation, abnormal reduced ejection fraction, or abnormal interventricular septal thickness, generating, by the model and based on the evaluation, a composite risk score reflecting a likelihood of the patient being diagnosed with one or more of the cardiology diseases within a predetermined period of time from when the electrocardiogram trace data was generated, and outputting the composite risk score to at least one of a memory or a display.

Claims (46)

1 . A method for evaluating electronic health data for a subject, the method comprising:

receiving, from a first source comprising at least one electronic health record, electronic health data associated with a subject;

generating at a first layer of a machine learning model, one or more labels, the one or more labels being generated based at least in part on the electronic health data, each label corresponding to a respective disease state;

generating, based at least in part on a first portion of the electronic health data and the one or more labels, indications of risk of two or more cardiac diseases;

identifying, based at least in part on the indications of risk, one or more of a monitoring or management procedure related to the disease state corresponding to the generated one or more labels; and

sending, to a recipient, a report, the report including the one or more of the monitoring or management procedures.

2 . The method of claim 1 , wherein generating the indications of risk includes providing to a second layer of the machine learning model, the first portion of the electronic health data and the one or more labels, the second layer being trained to generate the indications of risk based on electronic health data and associated labels,

wherein the indications of risk are generated at the second layer based on the first portion of the electronic health data and the one or more labels.

3 . The method of claim 1 , further comprising:

generating a notification to a recipient if the indications of risk exceed a first threshold,

wherein the notification includes the one or more of the monitoring or management procedures.

4 . The method of claim 3 , wherein the notification includes a timing interval in which to perform the one or more of the monitoring or management procedures.

5 . The method of claim 1 , wherein one of the one or more monitoring or management procedures is a diagnostic test for at least one cardiac disease of the two or more cardiac diseases.

6 . The method of claim 1 , wherein one of the one or more monitoring or management procedures is one of additional monitoring, a physical examination, an echocardiogram, or an echocardiograph.

7 . The method of claim 1 , further comprising:

providing at least a portion of the electronic health data to the first layer.

8 . The method of claim 1 , wherein the one or more labels include a condition label, the condition label including an abnormality and a severity.

9 . The method of claim 8 , wherein the one or more labels include a condition label corresponding to one or more cardiac valves of the subject.

10 . The method of claim 1 , further comprising:

receiving, from a second source, second health data of the subject, wherein the indications of risk are generated based at least in part on the second health data.

11 . The method of claim 10 , wherein the second source includes a plurality of subject data records, and wherein the second health data comprises electrocardiogram trace data of the subject.

12 . The method of claim 10 , wherein the first source is associated with a first entity, and wherein the second source is associated with a second entity.

13 . The method of claim 2 , further comprising, for each of the one or more monitoring or management procedures, generating, by the second layer, a clinical score associated with the one or more monitoring or management procedures based at least in part on the one or more labels.

14 . The method of claim 2 , further comprising, generating, by the second layer, and based at least in part on the one or more labels and a second portion of the electronic health data, second indications of risk, the second indications of risk being associated with a second one or more monitoring or management procedures for the subject, wherein the second portion of the electronic health data is not included in the first portion of the electronic health data.

15 . The method of claim 1 , wherein the electronic health data includes one or more of vitals data, laboratory data, comorbidities data, or demographic information of the subject.

16 . The method of claim 15 , wherein the vitals data comprises one or more of body mass index, systolic blood pressure, diastolic blood pressure, heart rate, height, weight, or smoking status,

wherein the laboratory data comprises one or more of A1C, bilirubin, blood urea nitrogen, cholesterol, creatine kinase myocardial band, creatinine, C-reactive protein, D-dimer, glucose, high-density lipoprotein, hemoglobin, high-density lipoprotein, lactate dehydrogenase, lymphocytes, potassium, pro B-type natriuretic peptide, sodium, troponin I and T, triglyceride, uric acid, very low-density lipoprotein, or estimated glomerular filtration rate, and

wherein the comorbidities data comprises one or more of heart failure, prior myocardial infarction, diabetes mellitus, chronic obstructive pulmonary disease, renal failure, prior echocardiogram, coronary artery disease, or hypertension.

17 . The method of claim 1 , further comprising determining a positive predictive value of the machine learning model for one or more subject populations, the subject populations being defined by one or more of a race, ethnicity, sex, or age.

18 . The method of claim 1 , further comprising:

training the machine learning model using a first subject population, a majority of the subject in the first subject population having a first demographic characteristic;

evaluating a predictive value of the machine learning model for subjects of a second subject population, a majority of the subjects in the second subject population not having the first demographic characteristic; and

if the predictive value of the machine learning model for the second subject population is below a predictive value threshold, modifying the model to at least partially account for differences between subjects of the first subject population and the second subject population.

19 . A system for evaluating electronic health data for a subject, the system comprising:

a computer including a processing device, the processing device configured to:

receive, from a first source comprising at least one electronic health record, electronic health data associated with a subject;

generate at a first layer of a machine learning model, one or more labels, the one or more labels being generated based at least in part on the electronic health data, each label corresponding to a respective disease state;

generate, based at least in part on a first portion of the electronic health data and the one or more labels, indications of risk of two or more cardiac diseases;

identify, based at least in part on the indications of risk, one or more of a monitoring or management procedure related to the disease state corresponding to the generated one or more labels; and

send, to a recipient, a report, the report including the one or more of the monitoring or management procedures.

20 . A non-transitory computer readable medium, comprising instructions for causing a computer to:

receive, from a first source comprising at least one electronic health record, electronic health data associated with a subject;

generate at a first layer of a machine learning model, one or more labels, the one or more labels being generated based at least in part on the electronic health data, each label corresponding to a respective disease state;

generate, based at least in part on a first portion of the electronic health data and the one or more labels, indications of risk of two or more cardiac diseases;

identify, based at least in part on the indications of risk, one or more of a monitoring or management procedure related to the disease state corresponding to the generated one or more labels; and

send, to a recipient, a report, the report including the one or more of the monitoring or management procedures.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded May 14, 2026
From: ARES CAPITAL CORPORATION, AS COLLATERAL AGENT
To: TEMPUS AI, INC. (F/K/A TEMPUS LABS, INC.)
Reel/Frame 075577/0513 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2026
From: ULLOA-CERNA, ALVARO; HAGGERTY, CHRISTOPHER; FORNWALT, BRANDON; CHEN, RUIJUN; PFEIFER, JOHN
To: GEISINGER CLINIC
Reel/Frame 074289/0001 →
SECURITY INTEREST Recorded Jun 2, 2025
From: TEMPUS AI, INC.
To: ARES CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 071468/0107 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2024
From: ZIMMERMAN, NOAH; LEE, GREG
To: TEMPUS LABS, INC.
Reel/Frame 066396/0313 →
CHANGE OF NAME Recorded Feb 6, 2024
From: TEMPUS LABS, INC.
To: TEMPUS AI, INC.
Reel/Frame 066507/0990 →
Continuity (5)
Continuation 17829351 · May 31, 2022
Provisional Application 63224850 · Jul 22, 2021
Provisional Application 63202436 · Jun 10, 2021
Provisional Application 63194923 · May 28, 2021
Related Publication 20230343464A1 · Oct 26, 2023
References Cited (120)
US 7801591B1 · Shusterman · 2010 [cited by examiner]
US 9764151B2 · Cappelaere · 2017 [cited by examiner]
US 10395772B1 · Lucas et al. · 2019 [cited by applicant]
US 10667680B2 · Gupta et al. · 2020 [cited by applicant]
US 10827982B2 · Sitek · 2020 [cited by applicant]
US 11972869B2 · Wagner et al. · 2024 [cited by applicant]
US 20070214013A1 · Silverman · 2007 [cited by applicant]
US 20090093686A1 · Hu et al. · 2009 [cited by applicant]
US 20100217144A1 · Brian · 2010 [cited by applicant]
US 20110295134A1 · DeBauche · 2011 [cited by applicant]
US 20150112182A1 · Sharma et al. · 2015 [cited by applicant]
US 20150235143A1 · Eder · 2015 [cited by applicant]
US 20150324527A1 · Siegel et al. · 2015 [cited by applicant]
US 20160022162A1 · Ong et al. · 2016 [cited by applicant]
US 20160135706A1 · Sullivan et al. · 2016 [cited by applicant]
US 20170281095A1 · An et al. · 2017 [cited by applicant]
US 20170357756A1 · Fidone et al. · 2017 [cited by applicant]
US 20180333104A1 · Sitek · 2018 [cited by applicant]
US 20190171936A1 · Karras et al. · 2019 [cited by applicant]
US 20200176122A1 · Teplitzky et al. · 2020 [cited by applicant]
US 20200226757A1 · Hare, II et al. · 2020 [cited by applicant]
US 20200337773A1 · Rawlinson et al. · 2020 [cited by applicant]
US 20200353271A1 · Dani et al. · 2020 [cited by applicant]
US 20200397313A1 · Attia et al. · 2020 [cited by applicant]
US 20210000347A1 · Stump · 2021 [cited by applicant]
US 20210027194A1 · Monaghan et al. · 2021 [cited by applicant]
US 20210059540A1 · Peterson et al. · 2021 [cited by applicant]
US 20210076960A1 · Fornwalt et al. · 2021 [cited by applicant]
US 20210085215A1 · Auerbach et al. · 2021 [cited by applicant]
US 20210085397A1 · Passerini et al. · 2021 [cited by applicant]
US 20210089921A1 · Aghdasi et al. · 2021 [cited by applicant]
US 20210110930A1 · Park et al. · 2021 [cited by applicant]
US 20210125722A1 · Sherkat et al. · 2021 [cited by applicant]
US 20210145404A1 · Fornwalt et al. · 2021 [cited by applicant]
US 20210150693A1 · Fornwalt et al. · 2021 [cited by applicant]
US 20210153761A1 · Jung et al. · 2021 [cited by applicant]
US 20210259560A1 · Venkatraman et al. · 2021 [cited by applicant]
US 20210345934A1 · Landgraf et al. · 2021 [cited by applicant]
US 20220189636A1 · Wagner et al. · 2022 [cited by applicant]
US 20220229071A1 · Rhyne et al. · 2022 [cited by applicant]
US 20240164688A1 · Asirvatham et al. · 2024 [cited by applicant]
CN 106510686A · 2017 [cited by applicant]
KR 20200077852A · 2020 [cited by applicant]
WO 2019118640A1 · 2019 [cited by applicant]
WO 2020004369A1 · 2020 [cited by applicant]
WO 2021071142A1 · 2021 [cited by applicant]
European Patent Office, Extended Search Report, Application No. 20866017.5, Sep. 20, 2023, 7 pages. [cited by applicant]
Zhang, Kathleen W., et al. “A multi-modal diagnostic model improves detection of cardiac amyloidosis among patients with diagnostic confirmation by cardiac biopsy.” American heart journal 232 (2021): 137-145. [cited by applicant]
Extended European Search Report in European Application No. 22812340.2; received on Jan. 22, 2025. [cited by applicant]
Raghunath et al., Deep Neural Networks can Predict New-Onset Atrial Fibrillation from the 12-lead ECG and Help Identify Those at Risk of Atrial Fibrillation-Related Stroke, Circulation, 2021, 143(13):1287-1298. [cited by applicant]
Reiffel et al., Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population: The REVEAL AF Study, JAMA Cardiology, 2017, 2:1120-1127. [cited by applicant]
Rembold, Number Needed to Screen: Development of a Statistic for Disease Screening, BMJ, 1998, 317:307-312. [cited by applicant]
Schnabel et al., Development of a Risk Score for Atrial Fibrillation in the Community; The Framingham Heart Study, Lancet, 2009, 373:739-745. [cited by applicant]
Schroder et al., Screening and Prostate-Cancer Mortality in a Randomized European Study, New England Journal of Medicine, 2009, 360:1320-1328. [cited by applicant]
Singer et al., ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and Design of the GUARD-AF Randomized Trial of Screening for Atrial Fibrillation with a 14-day… [cited by applicant]
Siu, Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement, Annals of Internal Medicine, 2016, 164:279-296. [cited by applicant]
Steinhubl et al., Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation: The mSToPS Randomized Clinical Trial, JAMA, 2018, 320(2):146-155. [cited by applicant]
Stewart et al., A Population-Based Study of the Long-term Risks Associated with Atrial Fibrillation: 20-Year Follow-up of the Renfrew/Paisley Study, American Journal of Medicine, 2002, 113:359-364. [cited by applicant]
Suresh et al., Advanced Cardiac Amyloidosis Associated with Normal Interventricular Septum Thickness: An Uncommon Presentation of Infiltrative Cardiomyopathy, J Am Soc Echocardiogr, 2014, 27(4):440-447. [cited by applicant]
Svennberg et al., Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study, Circulation, 2015, 131(25):2176-2184. [cited by applicant]
Topol, Digital Medicine—What's Lurking in Your Electrocardiogram?, The Lancet, 2021, 397:785. [cited by applicant]
Turakhia et al., Atrial Fibrillation Burden and Short-Term Risk of Stroke: Case-Crossover Analysis of Continuously Recorded Heart Rhythm from Cardiac Electronic Implanted Devices, Circ Arrhythmia Electrophysiol, 2015, 8… [cited by applicant]
US Preventive Services Task Force, Screening for Atrial Fibrillation, US Preventive Services Task Force Recommendation Statement, JAMA, 2022, 327(4):360-367. [cited by applicant]
Weimann et al., Transfer Learning for ECG Classification, Scientific Reports, 2021, 11:5251, pp. 1-12. [cited by applicant]
Wolf et al., Epidemiologic Assessment of Chronic Atrial Fibrillation and Risk of Stroke: The Framingham Study, Neurology, 1978, 28:973-977. [cited by applicant]
Wolf et al., Atrial Fibrillation as an Independent Risk Factor for Stroke: The Framingham Study, Stroke, 1991, 22(8):983-988. [cited by applicant]
Youden, Index for Rating Diagnostic Tests, Cancer, 1950, pp. 32-35. [cited by applicant]
PCT International Search Report and Written Opinion, PCT/US2020/051655, Dec. 22, 2020, 8 pages. [cited by applicant]
PCT International Search Report and Written Opinion, PCT/US2022/031663, Aug. 19, 2022, 15 pages. [cited by applicant]
PCT International Search Report and Written Opinion, PCT/US2022/031665, Aug. 19, 2022, 16 pages. [cited by applicant]
PCT International Search Report and Written Opinion, PCT/US2022/031670, Aug. 18, 2022, 9 pages. [cited by applicant]
Apple Inc., De Novo Classification Request for ECG App, 2018, 15 pages. [cited by applicant]
Alonso et al., Simple Risk Model Predicts Incidence of Atrial Fibrillation in a Racially and Geographically Diverse Population: The CHARGE-AF Consortium, J Am Heart Assoc, 2013, 2:e000102, 11 pages. [cited by applicant]
Arvanitis et al., Identification of V1221 (Val122lle) Transthyretin Cardiac Amyloidosis (ATTR) Using Serum Retinol-Binding Protein 4 (RBP4) and a Clinical Prediction Model, JAMA Cardiol., 2017, 2(3):305-313. [cited by applicant]
Ashburner et al., Design and Rationale of a Pragmatic Trial Integrating Routine Screening for Atrial Fibrillation at Primary Care Visits: The VITAL-AF Trial, American Heart Journal, 2019, 215:147-156. [cited by applicant]
Attia et al., An Artificial Intelligence-Enabled ECG Algorithm for the Identification of Patients with Atrial Fibrillation During Sinus Rhythm: A Retrospective Analysis of Outcome Prediction, The Lancet, 2019, 394(10201… [cited by applicant]
Britton et al., Non-Rheumatic Atrial Fibrillation as a Risk Factor for Stroke, Stroke, 1985, 16(2):182-188. [cited by applicant]
Chamberlain et al., A Clinical Risk Score for Atrial Fibrillation in a Biracial Prospective Cohort (From the Atherosclerosis Risk in Communities [ARIC] Study, Am J Cardiol, 2011, 107(1):85-91. [cited by applicant]
Chen et al., XGBoost: A Scalable Tree Boosting System, Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, 2016, pp. 785-794. [cited by applicant]
clinicaltrials.gov, Early Treatment of Atrial Fibrillation for Stroke Prevention Trial (EAST), NCT01288352, 2011, 10 pages. [cited by applicant]
clinicaltrials.gov, A Study to Determine if Identification of Undiagnosed Atrial Fibrillation in People at Least 70 Years of Age Reduces the Risk of Stroke, NCT04126486, 2019, 6 pages. [cited by applicant]
Connolly et al., Dabigatran Versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, 2009, 361:1139-1151. [cited by applicant]
Cox, Regression Models with Life Tables. Journal of the Royal Statistical Society, Series B (Methodological), 1972, 34(2):187-220. [cited by applicant]
Duchi et al., Adaptive Subgradient Methods for Online Learning and Stochastic Optimization, Journal of Machine Learning Research, 2011, 12:2121-2159. [cited by applicant]
Freedman et al., Stroke Prevention in Atrial Fibrillation, The Lancet, 2016, 388(10046):806-817. [cited by applicant]
Friberg et al., High Prevalence of Atrial Fibrillation Among Patients with Ischemic Stroke, Stroke, 2005, 45:2599-2605. [cited by applicant]
Gladstone et al., Screening for Atrial Fibrillation in the Older Population: A Randomized Clinical Trial, JAMA Cardiology, 2021, 6(5):558-567. [cited by applicant]
Gopinathannair et al., Arrhythmia-Induced Cardiomyopathies: Mechanisms, Recognition, and Management, J Am Coll Cardiol., 2015, 66:1714-1728. [cited by applicant]
Granger et al., Apixaban Versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, 2011, 365:981-992. [cited by applicant]
Guo et al., Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation, Journal of the American College of Cardiology, 2019, 74(19):2365-2375. [cited by applicant]
Hannon et al., Stroke Associated with Atrial Fibrillation—Incidence and Early Outcomes in the North Dublin Population Stroke Study, Cerebrovascular Diseases, 2010, 29:43-49. [cited by applicant]
Hart et al., Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation, Annals of Internal Medicine, 2007, 146:857-867. [cited by applicant]
Healey et al., Subclinical Atrial Fibrillation and the Risk of Stroke, New England Journal of Medicine, 2012, 366:120-129. [cited by applicant]
Heeringa et al., Prevalence, Incidence and Lifetime Risk of Atrial Fibrillation: The Rotterdam Study, European Heart Journal, 2006, 27:949-953. [cited by applicant]
Hindricks et al., 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS), European Heart Journal, 2020, 4… [cited by applicant]
Hobbs et al., A Randomised Controlled Trial and Cost-Effectiveness Study of Systematic Screening (Targeted and Total Population Screening) Versus Routine Practice for the Detection of Atrial Fibrillation in People Aged … [cited by applicant]
Huda et al., A Machine Learning Model for Identifying Patients at Risk for Wild-Type Transthyretin Amyloid Cardiomyopathy, Nature Communications, 2021, 12:2725, pp. 1-12. [cited by applicant]
Huizar et al., Arrhythmia-Induced Cardiomyopathy: JACC State-of-the-Art Review, J Am Coll. Cardiol., 2019, 73(18):2328-2344. [cited by applicant]
Ioffe et al., Batch Normalization: Accelerating Deep Network Training by Reducing Internal Covariate Shift, In International Conference on Machine Learning, 2015, pp. 448-456. [cited by applicant]
Kaplan et al., Nonparametric Estimation from Incomplete Observations, Journal of the American Statistical Association, 1958, 53(282):457-481. [cited by applicant]
Khurshid et al., ECG-Based Deep Learning and Clinical Risk Factors to Predict Atrial Fibrillation, Circulation, 2022, 145(2):122-133. [cited by applicant]
Kirchhof et al., 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration with EACTS, European Heart Journal, 2016, 37:2893-2962. [cited by applicant]
Koltowski et al., Kardia Mobile Applicability in Clinical Practice: A Comparison of Kardia Mobile and Standard 12-lead Electrocardiogram Records in 100 Consecutive Patients of a Tertiary Cardiovascular Care Center, Card… [cited by applicant]
Kottkamp, Human Atrial Fibrillation Substrate: Towards a Specific Fibrotic Atrial Cardiomyopathy, European Heart Journal, 2013, 34:2731-2738. [cited by applicant]
Krahn et al., The Natural History of Atrial Fibrillation: Incidence, Risk Factors, and Prognosis in the Manitoba Follow-Up Study, American Journal of Medicine, 1995, 98::476-484. [cited by applicant]
Kyriakou et al., Diagnosis of Cardiac Amyloidosis: A Systematic Review on the Role of Imaging and Biomarkers, BMC Cardiovascular Disorders, 2018, 18:221, pp. 1-11. [cited by applicant]
Lin et al., Newly Diagnosed Atrial Fibrillation and Acute Stroke: The Framingham Study, Stroke, 1995, 26:1527-1530. [cited by applicant]
Lin et al., Network in Network, In 2nd International Conference on Learning Representations, ICLR 2014—Conference Track Proceedings. 2014, 10 pages. [cited by applicant]
Lip et al., Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach: The Euro Heart Survey on Atrial Fibrillation, Chest, 2010, 137… [cited by applicant]
Lloyd-Jones et al., Lifetime Risk for Development of Atrial Fibrillation: The Framingham Heart Study, Circulation, 2004, 110:1042-1046. [cited by applicant]
Martini et al., Deep Learning to Diagnose Cardiac Amyloidosis from Cardiovascular Magnetic Resonance, Journal of Cardiovascular Magnetic Resonance, 2020, 22:84, pp. 1-11. [cited by applicant]
Meschia et al., Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals from the American Heart Association/American Stroke Association, Stroke, 2014, 45:3754-3832. [cited by applicant]
Morandi et al., X-ray, Lensing and Sunyaev-Zel'dovich Triaxial Analysis of Abell 1835 Out to R200, Mon Not R Astron Soc., 2012, 425:2069-2082. [cited by applicant]
Page et al., Asymptomatic Arrhythmias in Patients with Symptomatic Paroxysmal Atrial Fibrillation and Paroxysmal Supraventricular Tachycardia, Circulation, 1994, 89:224-227. [cited by applicant]
Patel et al., Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation, New England Journal of Medicine, 2011, 365:883-891. [cited by applicant]
Perez et al., Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation, New England Journal of Medicine, 2019, 381:1909-1917. [cited by applicant]
Poterucha et al., Deep Learning Analysis of Cardiac Testing for the Detection of Cardiac Amyloidosis, JACC, 2021, 77(18):529. [cited by applicant]
Prechelt, Early Stopping—But When? In: Neural Networks: Tricks of the Trade, Springer, 1998. pp. 55-69. [cited by applicant]
Raghunath et al., Deep Neural Networks can Predict Mortality from 12-lead Electrocardiogram Voltage Data, 2019, arXiv preprint arXiv:1904.07032, pp. 1-11. [cited by applicant]
Raghunath et al., Prediction of Mortality from 12-lead Electro Cardiogram Voltage Data Using a Deep Neural Network, Nature Medicine, 2020, 26(6):886-891. [cited by applicant]